Holen Sie sich die Stockscreener-App
329.89
3.07%
-10.44
Handel nachbörslich:
330.40
0.51
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$340.32
Offen:
$340.36
24-Stunden-Volumen:
2.89M
Relative Volume:
1.11
Marktkapitalisierung:
$177.64B
Einnahmen:
$35.89B
Nettoeinkommen (Verlust:
$7.01B
KGV:
25.50
EPS:
12.9352
Netto-Cashflow:
$11.54B
1W Leistung:
-4.51%
1M Leistung:
+3.14%
6M Leistung:
+14.90%
1J Leistung:
+20.25%
1-Tages-Spanne:
$328.63
$340.88
1-Wochen-Bereich:
$328.63
$346.38
52-Wochen-Spanne:
$253.30
$346.38
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Vergleichen Sie AMGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
329.89 | 183.17B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
A Closer Look at Amgen (AMGN) Valuation After Its 12-Month 28% Share Price Gain - simplywall.st
Erste Group upgrades Amgen stock rating to Buy from Hold on obesity drug - Investing.com
Amgen (NASDAQ:AMGN) Rating Increased to Buy at Erste Group Bank - MarketBeat
Amgen Named Official Biotech Partner by Los Angeles Sports & Entertainment Commission (LASEC) Ahead of FIFA World Cup 2026 - Amgen
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
What makes Amgen Inc. (AMG0) stock appealing to growth investorsMarket Performance Recap & Smart Money Movement Alerts - Newser
Is Amgen Inc. (AMG0) stock overpriced at current multiplesEarnings Risk Report & Long-Term Investment Growth Plans - Newser
First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN - MarketBeat
Beutel Goodman & Co Ltd. Raises Position in Amgen Inc. $AMGN - MarketBeat
Baird Financial Group Inc. Cuts Position in Amgen Inc. $AMGN - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report? - Yahoo Finance
Pharmaceutical Marketing Industry Trends and Emerging Opportunities 2025-2032 Featuring Syneos Health, McCann Health, Amgen, AXPIRA, Pfizer and MoreResearchAndMarkets.com - Markets Financial Content
Amgen (NASDAQ:AMGN) Shareholders Have Earned a 12% CAGR Over the Last Five Years - 富途牛牛
Amgen: Stagnation And The IRS Are Coming (NASDAQ:AMGN) - Seeking Alpha
Does Amgen Stock Lead the Pack? - Trefis
3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 - The Motley Fool
EverSource Wealth Advisors LLC Cuts Position in Amgen Inc. $AMGN - MarketBeat
Guggenheim Capital LLC Boosts Stake in Amgen Inc. $AMGN - MarketBeat
Will Strong Q3 Beat And Pipeline Updates Change Amgen's (AMGN) Future Earnings Narrative? - simplywall.st
BMO Capital Maintains Amgen (AMGN) Outperform Recommendation - Nasdaq
Amgen (NASDAQ:AMGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Benzinga
Key facts: Amgen reports strong growth; BMO raises price target to $372 - TradingView
Amgen stock hits 52-week high at $345.95 By Investing.com - Investing.com Nigeria
Amgen stock hits 52-week high at $345.95 - Investing.com
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally - ts2.tech
Biocon and Amgen Reach Deal to Commercialise Biosimilars in Europe - Chemical Industry Digest
BMO Capital Raises Price Target for Amgen (AMGN) to $372, Mainta - GuruFocus
BMO Capital Adjusts Price Target on Amgen to $372 From $335, Maintains Outperform Rating - marketscreener.com
Invesco Ltd. Buys 339,755 Shares of Amgen Inc. $AMGN - MarketBeat
UPC Court Of Appeal Overturns Revocation Of Amgen's PCSK9 Antibody Patent And Clarifies The UPC's Inventive Step Approach (Amgen v Sanofi And Regeneron) - MarketScreener
Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts - Insider Monkey
Extensive-Stage Small Cell Lung Cancer Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | EpicentRx, Ipsen, Bristol-Myers Squibb, Xcovery Holding Company, Amgen - Barchart.com
M&T Bank Corp Sells 61,385 Shares of Amgen Inc. $AMGN - MarketBeat
Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow - Amgen
OMERS ADMINISTRATION Corp Cuts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Biocon Biologics settles with Amgen to launch Denosumab Biosimilars in Europe, rest of the world - Zee Business
Biocon Biologics settles with Amgen Inc to commercialise biosimilars in Europe - Daily Excelsior
How the Story Behind Amgen Is Shifting After Pipeline and Guidance Updates - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Fisher Asset Management LLC - MarketBeat
Edgestream Partners L.P. Buys 12,318 Shares of Amgen Inc. $AMGN - MarketBeat
Beacon Pointe Advisors LLC Sells 4,768 Shares of Amgen Inc. $AMGN - MarketBeat
Is Amgen Inc. (AMG) stock supported by strong fundamentals2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser
Amgen (AMGN): Company Profile, Stock Price, News, Rankings - Fortune
How strong is Amgen Inc. (AMG0) stock earnings growthJuly 2025 Short Interest & Risk Controlled Swing Alerts - Newser
Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation - Express Pharma
Biocon Biologics announces settlement agreement with Amgen Inc. - Business Standard
Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast - ts2.tech
Is the Market Bullish or Bearish on Amgen Inc? - Benzinga
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amgen Inc-Aktie (AMGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
0.98%
1.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):